Infosys deepens its strategic ties with Telstra
Telstra provides telecommunication networks and other market-related products or services.
Infosys will become the strategic partner of Telstra to drive innovation in the company's operations by supporting Telstra's latest 'Connected Future 30 Strategy.'
This strategic collaboration will boost efficiency in Telstra's daily operations by streamlining the company's work. Reportedly, Infosys will adopt an AI-first approach to accelerate the pace of innovation in Telstra's work.
Chris Ellis (Head of IT and Software Engineering, Telstra) emphasized the expanded collaboration with Infosys to deliver great work value to both shareholders and customers.
On the other hand, Roary Stasko ( CEO, Telstra International) said, 'We are currently boosting our core capabilities and accelerating the transformation pace in the entire value chain for our customers. We will try to remain at the forefront of technological change.' Stakso added.
Rajan Shah (EVP and Industry Head of Global Markets, Infosys) pointed out this collaboration as the 'transformational journey' for Telstra to leverage and integrate the cutting-edge technologies of Infosys.
UNI SAS BM
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)
Business Standard
23 minutes ago
- Business Standard
Infosys shares slip even after Q1 beat; Here's why investors are wary
Shares of Infosys Ltd. declined on Thursday, despite analysts remaining positive after the company reported in-line first-quarter earnings. The drop was likely driven by trimmed revenue guidance, even as deal wins rose. Sentiment was further weighed down by a sharp sell-off in mid-cap peers following their results, dragging most stocks in the index lower. The information technology (IT) firm's stock fell as much as 1.16 per cent during the day to ₹1,556.1 per share. The stock pared losses to trade 0.8 per cent lower at ₹1,560 apiece, compared to a 0.2 per cent advance in Nifty 50 as of 9:50 AM. Meanwhile, the Nifty IT index fell 1.25 per cent, dragged down by Persistent Systems and Coforge, which declined 7.5 per cent and 6 per cent, respectively. Shares of Infosys were trading at the lowest level since June 6 this year. The counter has fallen 17 per cent this year, compared to a 6.4 per cent advance in the benchmark Nifty 50. The IT firm has a total market capitalisation of ₹6.48 trillion. Track LIVE Stock Market Updates Here Infosys Q1 results The net profit of Bengaluru-based company came in at ₹6,921 crore, marking a sequential decline of 1.6 per cent. The top line grew 3.3 per cent on quarter-on-quarter (Q-o-Q) to ₹42,279 crore. Both the numbers beat Bloomberg estimates, where analysts had estimated a net profit of ₹6,778 crore and revenue of ₹41,724 crore. For the IT giant, financial services and manufacturing, which contributed 28 per cent and 16 per cent to the top line, respectively, were up 5.6 per cent and 12.2 per cent. Growth in manufacturing was a contrast at a time when other companies have seen their revenue hammered due to tariff fears. Why did Infosys stock fall? As the tech firm only raised the lower end of its revenue guidance, analysts said that this reflects heightened global uncertainties. Despite productivity improvements and a 44 per cent sequential increase in deal wins, totalling $3.8 billion, Infosys narrowed its organic revenue growth guidance from 0-3 per cent to 0.6-2.6 per cent, analysts at JM Financial noted. At first glance, the cut at the upper end may seem negative. However, analysts said that a strong first quarter and normal seasonality suggest that the revised guidance is not relying on a second-half recovery. Symbolically, the narrower range also reflects greater confidence, JM Financial said. Analysts at Antique Stock Broking noted that although this was a good quarter, the organic guidance was largely unchanged. The narrow guidance reflects a mid-point increase in guidance from 1.5 per cent to 1.7 per cent. The revision accounts for a continued uncertain environment driven by tariff-related concerns, geopolitical risks, and lower third-party revenue, analysts said. Infosys narrowed its FY26 revenue growth guidance, reflecting its Q1 performance, robust large deal wins, M&A contribution, Emkay Global said in a note. The upper end of the guidance assumes macro stability, while the lower end factors in risks from further deterioration in the external environment, Emkay said.
The Hindu
23 minutes ago
- The Hindu
Markets trade lower in early deals on profit-taking in blue-chip stocks, foreign fund outflows
Benchmark indices Sensex and Nifty declined in early trade on Thursday (July 24, 2025) amid profit-taking in blue-chip stocks and continuous foreign fund outflows. Despite a positive start, the 30-share BSE Sensex failed to carry forward the momentum and fell later in the trade. The benchmark declined 130.92 points to 82,595.72 in early trade. The 50-share NSE Nifty dipped 23 points to 25,196.90. From the Sensex firms, Trent, Kotak Mahindra Bank, UltraTech Cement, Bajaj Finance, Tech Mahindra, Tata Consultancy Services, Infosys and Axis Bank were among the biggest laggards. However, Tata Motors, Eternal, Sun Pharma and Tata Steel were among the gainers. Infosys Ltd on Wednesday (July 23, 2025) reported an 8.7% rise in June quarter net profit and narrowed its full-year revenue forecast after stronger-than-expected earnings growth. In Asian markets, South Korea's Kospi, Japan's Nikkei 225 index, Shanghai's SSE Composite index and Hong Kong's Hang Seng were trading in positive territory. The U.S. markets ended higher on Wednesday (July 23, 2025). India and the U.K. will sign a free trade agreement on Thursday (July 24, 2025) in London that will allow export of labour-intensive products such as leather, footwear and clothing at concessional rates, while making imports of whisky and cars from Britain cheaper. The pact also helps double trade between the two economies to ₹120 billion by 2030. "U.S. striking trade deals with many countries is slowly removing concerns surrounding tariff wars. In the mother market U.S., good corporate earnings are providing the fundamental support to the market. Good Q1 numbers from Infosys can provide support to the weak IT index," VK Vijayakumar, Chief Investment Strategist, Geojit Investments Limited, said. Foreign Institutional Investors (FIIs) offloaded equities worth ₹4,209.11 crore on Wednesday (July 23, 2025), according to exchange data. However, Domestic Institutional Investors (DIIs) bought stocks worth ₹4,358.52 crore in the previous trade. Global oil benchmark Brent crude climbed 0.31% to ₹68.72 a barrel. On Wednesday (July 23, 2025), the Sensex jumped 539.83 points or 0.66% to settle at 82,726.64. The Nifty gained 159 points or 0.63% to settle at 25,219.90.
Economic Times
an hour ago
- Economic Times
Buy, Sell or Hold: Antique maintains Hold on Infosys; Nuvama maintains Buy on Dr Reddy's Laboratories
Live Events Antique on Infosys: Hold | Target price: Rs 1,750 Nuvama on Dr. Reddy's Laboratories: Buy | Target: Rs 1,486 | LTP: Rs 1,247 | Upside: 19% Motilal Oswal on Tata Consumer Products: Buy | Target: Rs 1,270 (earlier Rs 1,300) | LTP: Rs 1,062 | Upside: 19% (You can now subscribe to our (You can now subscribe to our ETMarkets WhatsApp channel Brokerages have shared their latest views on key Indian stocks, highlighting a mix of steady performance, emerging growth drivers, and sector-specific Antique has maintained a cautious stance on Infosys , citing margin pressures and limited changes in organic growth guidance, Nuvama remains optimistic about Dr. Reddy's Laboratories, driven by pipeline progress and a strong outlook for its CDMO Motilal Oswal has reiterated its bullish view on Tata Consumer Products , expecting margin expansion and synergies from recent acquisitions to support earnings a summary of their recommendations and insights for the next 12 have compiled key brokerage recommendations from ET Now and other sources:Antique has maintained a 'Hold' rating on Infosys with a target price of Rs 1,750. While the company delivered a strong quarterly performance, its organic growth guidance remains largely reported a robust total contract value (TCV) of $3.8 billion, reflecting solid deal bookings. However, discretionary spending remains weak, and the company continues to face margin headwinds. As a result, EPS estimates for FY26 and FY27 remain has maintained a 'Buy' rating on Dr. Reddy's Laboratories with a target price of Rs 1,486, implying a 19% upside from the last traded price of Rs 1, the company's Q1 performance was below expectations, new growth drivers are emerging. Semaglutide's progress in Canada remains on track, and a US filing for Abatacept is expected—both positive CDMO business is expected to contribute $100 million in FY26, with a target of reaching $300 million by FY30—a significant upside the company has reaffirmed its 25% margin guidance, backed by ongoing cost optimisation Oswal has reiterated its 'Buy' rating on Tata Consumer Products, revising the target price slightly to Rs 1,270 from Rs 1,300, indicating a 19% upside from the current price of Rs 1, brokerage expects moderating tea prices to support margin expansion starting Q2FY26. Consolidated margins are likely to improve, led by the tea business, while the international segment is expected to sustain its from the integration of Capital Foods and Organic India are also expected to boost the domestic food segment. The company has guided for ~16% EBITDA margin by has accordingly raised its EBITDA estimates for FY26 and FY27 by 7% and 3%, respectively.
